XML 53 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Sale of Commercial Business - Additional Information (Detail)
3 Months Ended 6 Months Ended
Apr. 05, 2017
USD ($)
Apr. 03, 2017
USD ($)
ft²
Jan. 08, 2017
Employee
May 05, 2011
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 22, 2015
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Aggregate principal amount outstanding redeemed           $ 175,000,000  
Dividend date declared           Apr. 05, 2017  
Special cash dividend paid $ 140,000,000            
Dividend paid date           May 26, 2017  
Dividend payable, date of record           May 17, 2017  
January 2017 Corporate Restructuring [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Restructuring activity, announcement date           Jan. 08, 2017  
Restructuring and related cost, headcount reduction percentage     30.00%        
Restructuring and related cost, number of employees after headcount reduction | Employee     80        
January 2017 Corporate Restructuring [Member] | Discontinued Operations [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Restructuring expenses           $ 9,500,000  
January 2017 Corporate Restructuring [Member] | Contractual Termination Benefits [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Restructuring expenses         $ 4,200,000 $ 9,500,000  
January 2017 Corporate Restructuring [Member] | One-time Employee Termination Benefits [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Restructuring And Related Activities Description           One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The majority of these payments were made during the second quarter of 2017. The remaining payments represent severance payments that will be paid over one year.  
Severance payments payment period           1 year  
2022 Notes [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Interest rate (as a percent)             11.50%
Asset Sale Agreement [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Transition services agreement period   24 months          
Special cash dividend paid   $ 140,000,000          
Gain from discontinued operations           $ 598,200,000  
Asset Sale Agreement [Member] | 2022 Notes [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Aggregate principal amount outstanding redeemed   175,000,000          
Additional premium payment   $ 20,100,000          
Interest rate (as a percent)   11.50%          
Aggregate principal amount of interest redeemed   $ 7,400,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Manufacturing Facility [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Area of sublease property | ft²   70,237          
Lease expiration date   Jun. 30, 2019          
Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Pancreas as First-Line Treatment [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Additional payments receivable on achievement of certain milestone events   $ 225,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Small Cell Lung Cancer [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Additional payments receivable on achievement of certain milestone events   150,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Other Unrelated Clinical Trials [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Additional payments receivable on achievement of certain milestone events   75,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Development and Commercialization Milestones [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Maximum amount of milestone payments that can be received   33,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Sale Milestones in Major European Countries [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Potential milestone payments receivable   18,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Sale Milestones in Major Non-European and Non-Asian Country [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Potential milestone payments receivable   5,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Clinical Trials in Lung Cancer [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Potential milestone payments receivable   10,000,000          
Ipsen [Member] | Asset Sale Agreement [Member] | Maximum [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Additional payments receivable on achievement of certain milestone events   $ 450,000,000          
PharmaEngine [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Upfront license fees paid       $ 10,000,000      
PharmaEngine [Member] | Development and Regulatory Milestone [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Maximum milestone payment obligation       80,000,000      
PharmaEngine [Member] | Sales Milestone [Member]              
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]              
Maximum milestone payment obligation       $ 130,000,000